Table 4.
Efficacy of NEPA in gender/age emetic risk groups.
| Overall (0–120 h) CR % of patients |
NEPA + DEX | Oral PALO + DEX | % Difference (95% CI) |
|---|---|---|---|
|
Females <55 years
(high risk) (N = 100/100) |
80.0 | 69.0 | 11.0 (−1.0; 23.0) |
|
Females ≥55 years
(moderate risk) (N = 108/103) |
84.5 | 69.4 | 15.0 (3.9; 26.2) |
|
Males <55 years
(low risk) (N = 91/126) |
89.7 | 71.4 | 18.3 (7.6; 29.0) |
|
Males ≥55 years
(lowest risk) (N = 206/153) |
92.8 | 81.1 | 11.7 (5.0; 18.5) |
NEPA: netupitant/palonosetron; PALO: palonosetron; CR: complete response; CI: confidence interval.